Study on Belzutifan for Advanced Kidney Cancer

Inclusion Criteria

• Diagnosed with advanced kidney cancer with a clear cell component.
• Have measurable cancer as determined by specific medical criteria.
• Able to provide a tumor sample for analysis.
• Cancer has worsened after previous treatment with specific immune therapies.
• Have received no more than three prior treatments for advanced kidney cancer.
• Have only received one prior immune therapy for advanced kidney cancer.
• Have recovered from side effects of previous treatments to a mild level.
• Have a performance status score of at least 70%, indicating the ability to care for oneself.
• Male participants must agree to use contraception or abstain from sex during the study and for at least 7 days after the last dose.
• Female participants must not be pregnant or breastfeeding and must agree to use contraception during the study and for at least 30 days after the last dose.
• Women of childbearing potential must have a negative pregnancy test before starting the study.

Exclusion Criteria

• Have low oxygen levels or need oxygen therapy.
• Have another progressing cancer or have been treated for another cancer in the past 3 years, except for certain skin cancers or in situ cancers.
• Have cancer that has spread to the brain or spinal cord.
• Have significant heart disease or recent heart attack.
• Have moderate to severe liver problems.
• Have used certain growth factors within 28 days before starting the study.
• Have psychiatric or substance abuse issues that would interfere with the study.
• Cannot swallow pills or have digestive issues affecting absorption.
• Have allergies to belzutifan or its components.
• Have previously been treated with belzutifan or similar drugs.
• Have used certain cancer treatments or participated in another study recently.
• Have an active infection or tuberculosis.
• Have an immune deficiency or history of HIV, hepatitis B, or hepatitis C.
• Have any condition or treatment that might interfere with the study or not be in the participant's best interest.